SG3 Management’s ChemoCentryx, Inc. CCXI Stock Holding History

SG3 Management’s Portfolio CCXI Stock Details CCXI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-20,000	Closed	-$496K	–	501
2022 Q2	$496K	Buy	+20,000	New	+$441K	0.06%	208
2022 Q1	–	Sell	-16,300	Closed	-$593K	–	1488
2021 Q4	$593K	Sell	16,300 -233,200	-93%	-$8.19M	0.01%	597
2021 Q3	$4.27M	Sell	249,500 -52,700	-17%	-$821K	0.13%	159
2021 Q2	$4.05M	Buy	302,200 +299,500	+11,093%	+$7.38M	0.14%	166
2021 Q1	$138K	Buy	+2,700	New	+$162K	﹤0.01%	1021
2020 Q4	–	Sell	-57,600	Closed	-$3.16M	–	1275
2020 Q3	$3.16M	Buy	+57,600	New	+$3.1M	0.12%	200

Other funds holding CCXI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

SFM

Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

SG3 Management's CCXI Position: Q3 2022 in Review

SG3 Management sold out of ChemoCentryx, Inc. (CCXI) in Q3 2022, closing a stake of 4,000 shares — an estimated $99K sold.

SG3 Management first reported a position in CCXI in Q2 2020 and held it in 5 quarters. The position peaked at $1.1M in Q3 2020. 217 funds tracked by Wall St. Rank hold CCXI as of Q3 2022.

SG3 Management reported no remaining ChemoCentryx, Inc. position as of Q3 2022 after selling out during the quarter.
SG3 Management sold 4,000 ChemoCentryx, Inc. shares in Q3 2022, an estimated $99K.
SG3 Management first reported a position in ChemoCentryx, Inc. in Q2 2020 and held it in 5 quarters.
SG3 Management's ChemoCentryx, Inc. position peaked at $1.1M in Q3 2020.
217 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q3 2022.

Based on SG3 Management's 13F filing for Q3 2022, filed 14 Nov 2022.